argenx SE is a biotechnology company that represents a strong set of values and corporate philosophy. With a focus on patients, collaboration, and innovation, argenx aims to transform the lives of people suffering from severe autoimmune diseases and cancer. The company is committed to developing breakthrough therapies based on its unique antibody engineering platform. By combining cutting-edge science, strategic partnerships, and a patient-centered approach, argenx strives to create meaningful impact in the healthcare industry. With its dedication to excellence and a relentless pursuit of scientific advancements, argenx SE has become a leading player in the biotech sector.

argenx SE is primarily present in various countries and regions around the world. The company has a global presence, with key operations and offices located in Europe, particularly in Belgium and the Netherlands. Additionally, argenx SE has expanded its footprint to North America, with offices and clinical development activities in the United States. Through its international presence, argenx SE aims to capitalize on the opportunities available in different markets and establish a strong presence in the biotechnology and pharmaceutical industry.

argenx SE has achieved several significant milestones in its history. It successfully completed a Phase 3 clinical trial for its product candidate efgartigimod, which demonstrated positive results in the treatment of generalized myasthenia gravis. The company also obtained breakthrough therapy designation from the U.S. FDA for efgartigimod in the same indication. Furthermore, argenx SE entered into strategic collaborations with multiple pharmaceutical companies to develop and commercialize its innovative antibody-based therapies. These partnerships include agreements with Janssen for cusatuzumab, Cilag GmbH International for ARGX-112, and Leo Pharma for ARGX-112. Overall, argenx SE has made significant strides in its quest to develop transformative medicines for patients.

argenx SE is a renowned biotechnology company with a rich history and significant accomplishments. Founded in 2008, argenx focuses on the discovery and development of innovative antibody-based therapeutics to benefit patients with severe autoimmune diseases and cancer. The company utilizes its unique Simple Antibody platform to engineer and manufacture differentiated therapeutic antibodies. Throughout its history, argenx has achieved numerous milestones, including successful clinical trials and collaborations with leading pharmaceutical companies. With its dedicated team of scientists and commitment to scientific excellence, argenx SE continues to make groundbreaking contributions in the field of biotechnology.

The main competitors of argenx SE in the market include companies such as Genmab A/S, Alexion Pharmaceuticals Inc., and MorphoSys AG.

argenx SE is primarily active in the pharmaceutical and biotechnology industries.

The business model of argenx SE revolves around developing and commercializing innovative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. With an emphasis on the discovery and development of uniquely differentiated antibody-based therapies, argenx combines its expertise in immunology and antibody engineering to target specific disease indications. The company focuses on both in-house discovery programs as well as collaborations with global partners to advance its pipeline of potential breakthrough treatments. By leveraging its expertise and strategic partnerships, argenx aims to bring transformative therapies to market and improve the lives of patients suffering from severe diseases.

De argenx K/W is -153,50.

De argenx KUV is 13,31.

De AlleAktien Kwaliteitsscore voor argenx is 5/10.

De verwachte argenx omzet is 1,90 mld. USD.

De verwachte argenx winst is -164,48 mln. USD.

argenx SE is a biopharmaceutical company involved in the development and commercialization of therapeutic antibodies. The company operates in various areas, including antibody discovery, data collection, clinical development, manufacturing, and drug marketing. Their research focuses on autoimmune diseases, inflammatory diseases, and cancer. arGEN-X has successfully completed numerous clinical trials and has a wide range of products in various stages of development. The company also seeks partnerships with other biopharmaceutical companies to accelerate the development of new products. Their goal is to discover, develop, and market novel antibodies to treat seriously ill patients.

argenx keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor argenx of het bedrijf keert geen dividend uit.

De ISIN van argenx is NL0010832176.

Het WKN van argenx is A11602.

De ticker van argenx is ARGX.BR.

Binnen de laatste 12 maanden betaalde argenx een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal argenx naar verwachting een dividend van 0 USD betalen.

De dividendrendement van argenx is momenteel .

argenx betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

argenx betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

argenx wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van argenx van 5-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 5-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 5-7-2024.

In het jaar 2023 heeft argenx 0 USD aan dividenden uitgekeerd.

De dividenden van argenx worden in USD uitgekeerd.